The introduction of Integrated Care Systems in July 2022 is a significant reform of health services in UK.It introduces the audit of the Integrated Care Systems by the UK's National Audit Office,including risk assessment,conclusions and recommendations in order to provide reference for public policy prospective audit and medical system reform and development in China.

The introduction of Integrated Care Systems in July 2022 is a significant reform of health services in UK.It introduces the audit of the Integrated Care Systems by the UK's National Audit Office,including risk assessment,conclusions and recommendations in order to provide reference for public policy prospective audit and medical system reform and development in China.

The introduction of Integrated Care Systems in July 2022 is a significant reform of health services in UK.It introduces the audit of the Integrated Care Systems by the UK's National Audit Office,including risk assessment,conclusions and recommendations in order to provide reference for public policy prospective audit and medical system reform and development in China.

The introduction of Integrated Care Systems in July 2022 is a significant reform of health services in UK.It introduces the audit of the Integrated Care Systems by the UK's National Audit Office,including risk assessment,conclusions and recommendations in order to provide reference for public policy prospective audit and medical system reform and development in China.

The introduction of Integrated Care Systems in July 2022 is a significant reform of health services in UK.It introduces the audit of the Integrated Care Systems by the UK's National Audit Office,including risk assessment,conclusions and recommendations in order to provide reference for public policy prospective audit and medical system reform and development in China.

The introduction of Integrated Care Systems in July 2022 is a significant reform of health services in UK.It introduces the audit of the Integrated Care Systems by the UK's National Audit Office,including risk assessment,conclusions and recommendations in order to provide reference for public policy prospective audit and medical system reform and development in China.

The introduction of Integrated Care Systems in July 2022 is a significant reform of health services in UK.It introduces the audit of the Integrated Care Systems by the UK's National Audit Office,including risk assessment,conclusions and recommendations in order to provide reference for public policy prospective audit and medical system reform and development in China.

The introduction of Integrated Care Systems in July 2022 is a significant reform of health services in UK.It introduces the audit of the Integrated Care Systems by the UK's National Audit Office,including risk assessment,conclusions and recommendations in order to provide reference for public policy prospective audit and medical system reform and development in China.

Objective To evaluate the application value of simultaneous amplification and testing for Myco-bacterium tuberculosis(SAT-TB)in evaluating the curative effect of initial treatment of smear-positive pul-monary tuberculosis patients.Methods A total of 62 newly treated smear positive pulmonary tuberculosis pa-tients from June 2022 to June 2023 in Guangzhou Panyu District Chronic Disease Control Station were selected as the study objects,and the curative effect was evaluated by liquid-based sandwich cup method,Roche culture method and SAT-TB detection method.All patients received the standard anti-tuberculosis treatment regimen of 2HRZE/4HR standard regimen,and sputum samples were detected by liquid-based sandwich cup method,Roche culture method,and SAT-TB detection method at the 2nd,4th,and 8th week of treatment,respectively.Results Among 62 patients,54 cases were positive and 8 cases were negative using Roche culture method,47 cases were positive and 15 cases were negative using SAT-TB detection method.60 cases were positive and 2 cases were negative by Mycobacterium tuberculosis(MTB)-DNA test.The positive rates of the three methods were 87.10％(54/62),75.81％(47/62)and 96.77％(60/62),respectively.Taking Roche culture method re-sults as the standard,the sensitivity of SAT-TB detection method and MTB-DNA was 97.87％(46/47)and 90.00％(54/60),and the specificity was 46.67％(7/15)and 100.00％(2/2),respectively.There were signifi-cant differences between Roche culture method and SAT-TB detection method and MTB-DNA test(x2=20.070,P＜0.05,x2=13.985,P＜0.05),the difference between the results of SAT-TB detection method and MTB-DNA test was also statistically significant(x2=8.365,P＜0.05).The negative conversion rates of MTB in sputum samples were 69.35％(43/62),29.03％(18/62)and 41.94％(26/62)at the 2nd,4 th,and 8 th weeks,respectively.77.42％(48/62),59.68％(37/62),58.06％(36/62),82.26％(51/62),79.03％(49/62),75.81％(47/62).There were significant differences in the negative conversion rates of MTB in sputum sam-ples between SAT-TB and liquid-based sandwich cup method at the 2nd and 4th weeks(x2=8.365,P＜0.05,x2=4.465,P＜0.05),while there was no significant difference between the results of Roche culture method at the 2nd,4th and 8th weeks(x2=1.726,P＞0.05,x2=0.000,P＞0.05,x2=0.046,P＞0.05).Conclusion The use of SAT-TB detection method in clinical practice to evaluate the efficacy of smear positive pulmonary tuberculo-sis patients could accurately and quickly assess the negative conversion rate and treatment effect of patients,and provide a reliable basis for guiding clinical treatment.It could be considered as an effective auxiliary diag-nosis and evaluation method of curative effect,worthy of promotion and practical application.

OBJECTIVE To explore the pharmaceutical care model for elderly patients with drug-related problems （DRPs） based on the comprehensive medication management review （CMMR）， and to observe the effect of pharmaceutical care under the model. METHODS The pharmaceutical care new model for elderly patients was established by concerning CMMR guidelines in Australia. In other words， clinical pharmacists receive medical care through referral by health practitioners and active consultation by patients or their caregivers. Visits were made by a combination of face-to-face and telephone interviews. Follow-up was carried out in the form of outpatient follow-up， telephone follow-up， appointment， and home guidance to know about the treatment of DRPs by healthcare practitioners or patients.Under this model， the occurrence status and classification of DRPs in elderly patients were studied through cross-sectional investigation. The effect of pharmaceutical care was evaluated from the aspects of hospitalization rate， adverse drug reaction （ADR） incidence，medication compliance， the number of medications， blood lipid level， etc.， through self-before-after comparison. RESULTS In this study， a patient-centered， evaluation-intervention-reevaluation closed-loop pharmaceutical care model was formed. Among 317 study subjects， the average number of DRPs was 1.03 （0-7） cases. Compared before and after the intervention， the number of drug types increased from 2.00（0.00，3.00） to 2.00（1.00，3.00）， but the level of low-density lipoprotein cholesterin in patients decreased from 3.48 （2.58， 4.29） mmol/L to 3.11 （2.29，3.81） mmol/L （P＜0.05）. There was no statistical significance in hospitalization rate， ADR incidence within or medication compliance. CONCLUSIONS CMMR-based pharmaceutical care model can effectively identify and manage the patients’ DRPs and reduce the level of blood lipid.